GlassScriptPhysician profile
Anthony T Shih
NPI 1710023049
$17,860.86
in general payments reported to CMS, 2019-2025
37 companies · $1,811 in 2025
The $1,811 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,671 · 2020: $2,097 · 2021: $3,002 · 2022: $2,757 · 2023: $1,658 · 2024: $1,865 · 2025: $1,811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,333.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,546.87 | 2019-2025 | Watchman Flx, General - Therapies, Watchman Access System |
| Abbott Laboratories | $1,615.07 | 2019-2025 | Jot Dx, Aveir |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,572.94 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,074.66 | 2019-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $965.77 | 2019-2023 | Leqvio |
| Medtronic, INC. | $954.23 | 2021-2025 | Linq II, Micra, Reveal Linq |
| Amarin Pharma, INC. | $895.96 | 2019-2020 | |
| Amgen INC. | $742.22 | 2019-2023 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $620.43 | 2021-2025 | |
| Biotronik INC. | $579.88 | 2019-2024 | Acticor 7 Vr-T Dx |
| Pfizer INC. | $573.10 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $488.10 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $427.63 | 2019-2024 | Xarelto |
| Cvrx, INC. | $350.35 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $255.16 | 2019-2025 | Camzyos |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $251.18 | 2024-2025 | Inspire |
| Silk Road Medical, INC. | $172.51 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Arbor Pharmaceuticals, INC. | $172.39 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $170.79 | 2019-2024 | Opsumit |
| Alexion Pharmaceuticals, INC. | $161.09 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $151.71 | 2019-2020 | |
| Gilead Sciences, INC. | $137.31 | 2019 | |
| Janssen Scientific Affairs, LLC | $136.71 | 2023 | Xarelto |
| Lundbeck LLC | $127.13 | 2019-2020 | |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Philips North America LLC | $120.86 | 2020-2025 | Extended Holter |
| Sanofi-Aventis U.S. LLC | $95.03 | 2019 | |
| Terumo Medical Corporation | $94.06 | 2025 | Angio-Seal, Azur Cx Detachable, Glidewire |
| Novo Nordisk INC | $66.32 | 2024-2025 | Ozempic |
| Regeneron Healthcare Solutions, INC. | $55.70 | 2019 | |
| Edwards Lifesciences Corporation | $29.07 | 2019 | |
| Allergan, INC. | $28.66 | 2019 | |
| Portola Pharmaceuticals, LLC | $28.03 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $26.03 | 2023 | Inpefa |
| Daiichi Sankyo INC. | $19.11 | 2019 | |
| Merck Sharp & Dohme LLC | $15.69 | 2023 | Verquvo |
| Cook Medical LLC | $14.11 | 2025 | Zilver Vena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Shih listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.